IMNM Stock Analysis: Immunome | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.434m USD | 12M Return: 180.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 32.0M
Qual. Beats: 1
Rev. Trend: -42.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Immunome, Inc. (NASDAQ: IMNM) is a U.S.-based biotechnology company focused on discovering, developing, and commercializing antibody-drug conjugates (ADCs) and other oncology therapeutics. Its lead clinical asset, Varegacestat, is a gamma secretase inhibitor currently in Phase 3 trials for desmoid tumors, while IM-1021, a ROR1-targeted ADC, is in Phase 1 development. The company is also advancing several preclinical candidates, including a FAP-targeted radioligand therapy (IM-3050) and additional solid tumor ADCs (IM-1617, IM-1340, and IM-1335).
Founded in 2006 and headquartered in Bothell, Washington, Immunome went public in October 2020 and operates within the Health Care / Biotechnology GICS sub-industry. As a clinical-stage biotech, its business model centers on advancing a pipeline of targeted cancer therapies through trials toward potential commercialization, with ADCs representing a class of oncology drugs that combine the targeting specificity of antibodies with potent cytotoxic agents.
- Varegacestat Phase 3 data readout in desmoid tumors
- ADC pipeline expansion with IM-1021 advancing through trials
- Cash runway supports clinical development through key milestones
| Net Income: -224.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.33 > 0.02 and ΔFCF/TA 14.00 > 1.0 |
| NWC/Revenue: 14.1k% < 20% (prev 2.67k%; Δ 11.4k% < -1%) |
| CFO/TA -0.32 > 3% & CFO -196.5m > Net Income -224.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 21.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (113.1m) vs 12m ago 42.47% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.83% > 50% (prev 3.19%; Δ -2.36% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.91 (Total Current Assets 594.3m - Total Current Liabilities 27.4m) / Total Assets 619.8m |
| B: -1.26 (Retained Earnings -782.0m / Total Assets 619.8m) |
| C: -0.47 (EBIT TTM -224.6m / Avg Total Assets 481.2m) |
| D: 18.93 (Book Value of Equity 588.7m / Total Liabilities 31.1m) |
| Altman-Z'' = 18.62 = AAA |
As of July 08, 2026, the stock is trading at USD 24.39 with a total of 1,540,020 shares traded. Over the past week, the price has changed by +15.92%, over one month by +31.06%, over three months by +13.02% and over the past year by +180.67%.
Current recommended Stop Loss: 21.20 (which is 13.1% or 2.8 ATR below the current price).
Immunome has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy IMNM.
- StrongBuy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35.8 | 46.7% |
P/S = 606.1646
P/B = 4.1304
Revenue TTM = 4.01m USD
EBIT TTM = -224.6m USD
EBITDA TTM = -221.8m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 3.69m USD (from shortLongTermDebtTotal, last quarter) (leases 3.69m already included)
Net Debt = -579.0m USD (calculated: Debt 3.69m - CCE 582.7m)
Enterprise Value = 1.85b USD (2.43b + Debt 3.69m - CCE 582.7m)
Interest Coverage Ratio = unknown (Ebit TTM -224.6m / Interest Expense TTM 0.0)
EV/FCF = -9.02x (Enterprise Value 1.85b / FCF TTM -205.5m)
FCF Yield = -11.08% (FCF TTM -205.5m / Enterprise Value 1.85b)
FCF Margin = -5.12k% (FCF TTM -205.5m / Revenue TTM 4.01m)
Net Margin = -5.59k% (Net Income TTM -224.6m / Revenue TTM 4.01m)
Gross Margin = unknown ((Revenue TTM 4.01m - Cost of Revenue TTM 51.4m) / Revenue TTM)
Tobins Q-Ratio = 2.99 (Enterprise Value 1.85b / Total Assets 619.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 3.69m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -177.4m (EBIT -224.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 21.68 (Total Current Assets 594.3m / Total Current Liabilities 27.4m)
Debt / Equity = 0.01 (Debt 3.69m / totalStockholderEquity, last quarter 588.7m)
Debt / EBITDA = 2.61 (negative EBITDA) (Net Debt -579.0m / EBITDA -221.8m)
Debt / FCF = 2.82 (negative FCF - burning cash) (Net Debt -579.0m / FCF TTM -205.5m)
Total Stockholder Equity = 439.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.67% (Net Income -224.6m / Total Assets 619.8m)
RoE = -51.15% (Net Income TTM -224.6m / Total Stockholder Equity 439.1m)
RoCE = -37.91% (EBIT -224.6m / Capital Employed (Total Assets 619.8m - Current Liab 27.4m))
RoIC = -29.96% (negative operating profit) (NOPAT -177.4m / Invested Capital 592.2m)
WACC = 10.46% (E(2.43b)/V(2.44b) * Re(10.48%) + D(3.69m)/V(2.44b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 107.3%
[DCF] Fair Price = unknown (Cash Flow -205.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.90 | # QB: 1
Revenue Correlation: -42.34 | Revenue CAGR: -15.06% | SUE: -0.10 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.50 | Chg30d=-6.95% | Revisions=+75% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-0.56 | Chg30d=-4.85% | Revisions=+62% | Analysts=12
EPS current Year (2026-12-31): EPS=-2.12 | Chg30d=-0.82% | Revisions=+67% | GrowthEPS=+12.6% | GrowthRev=-60.9%
EPS next Year (2027-12-31): EPS=-2.10 | Chg30d=-2.05% | Revisions=+42% | GrowthEPS=+1.3% | GrowthRev=+2379.2%
[Analyst] Revisions Ratio: +74% (up=36, down=4)